

05-31-2001



101734252

Patent No.: 5,750,360)
Issued: May 12, 1998)
Atty. File No.: 4588-7)
For: "METHOD FOR QUANTITATIVELY)
MEASURING APOPTOSIS")

BOX ASSIGNMENTS
Commissioner of Patents
Washington, D.C. 20231

Dear Sir:

Please record the attached original documents or copy thereof:

1. Name of conveying party(ies):

LXR Biotechnology, Inc.

2. Name and address of receiving party(ies):

Tanox, Inc.
10301 Stella Link
Houston, Texas 77025

3. Nature of Conveyance:

<input checked="" type="checkbox"/>	Assignment	<input type="checkbox"/>	Merger
<input type="checkbox"/>	Security Agreement	<input type="checkbox"/>	Change of Name
<input type="checkbox"/>	Other:_____		

Execution Date: May 2, 2001

4. Application number(s) or patent number(s)

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s): 08/470,865; 09/633,200; 08/937,067;
09/367,750; 09/381,488

B. Patent No.(s): 6,015,687; 5,770,443; 5,998,131; 5,663,070;
5,652,210; 5,637,486; 5,620,888; 5,681,703;
5,750,360

5. Name and address of party to whom correspondence concerning documents should be mailed:

Angela Dallas-Pedretti
Sheridan Ross P.C.
1560 Broadway, Suite 1200
Denver, Colorado 80202-5141

6. Total number of applications and patents involved: 14.

7. Total fee (37 CFR 3.41).....\$560.00.

☒ Enclosed

☒ Any deficiency in payment of recording fee is authorized to be charged to Deposit Account.

☐ Authorized to be charged to deposit account.

8. Deposit account number: 19-1970.

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Total number of pages including cover sheet, attachments and document: 7

Respectfully submitted,

SHERIDAN ROSS P.C.

By: Angela Dallas-Pedretti
Angela Dallas-Pedretti
Registration No. 42,460
1560 Broadway, Suite 1200
Denver, CO 80202-5141
(303) 863-9700

Date: May 21, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.: 6,015,687)
Issued: January 18, 2000)
Atty. File No.: 4588-1-1DIV1)
For: "NOVEL APOPTOSIS-MODULATING)
PROTEINS, DNA ENCODING THE)
PROTEINS AND METHODS OF USE)
THEREOF")

Serial No.: 08/470,865)
Filed: June 6, 1995)
Atty. File No.: 4588-1-1DIV2)
For: "NOVEL APOPTOSIS-MODULATING)
PROTEINS, DNA ENCODING THE)
PROTEINS AND METHODS OF USE)
THEREOF")

Patent No.: 5,770,443)
Issued: June 23, 1998)
Atty. File No.: 4588-1-1DIV3)
For: "NOVEL APOPTOSIS-MODULATING)
PROTEINS, DNA ENCODING THE)
PROTEINS AND METHODS OF USE)
THEREOF")

Serial No.: 09/633,200)
Filed: August 7, 2000)
Atty. File No.: 4588-1-1DIV4)
For: "NOVEL APOPTOSIS-MODULATING)
PROTEINS, DNA ENCODING THE)
PROTEINS AND METHODS OF USE)
THEREOF")

Patent No.: 5,998,131)
Issued: December 7, 1999)
Atty. File No.: 4588-1-2-FWC)
For: "METHODS OF SCREENING FOR)
THERAPEUTIC AGENTS USING NOVEL)
APOPTOSIS-MODULATING PROTEINS")

Serial No.: 08/937,067)
Filed: September 24, 1997)
Atty. File No.: 4588-2)
For: "FAMILY OF GENES ENCODING)
APOPTOSIS-RELATED PEPTIDES,)
PEPTIDES ENCODED THEREBY AND)
METHODS OF USE THEREOF")

RECORDATION OF ASSIGNMENT

CERTIFICATE OF MAILING	
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 ON <u>5/22/01</u> SHERIDAN ROSS, P.C.	
BY:	<i>Kathleen Farrell</i>

24

Serial No.: 09/367,750)
Filed: August 18, 1999)
Atty. File No.: 4588-3-PUS)
For: "BAK PROMOTER EXPRESSION SYSTEM")

Serial No.: 09/381,488)
Filed: September 20, 1999)
Atty. File No.: 4588-4-PUS)
For: "NOVEL BAK BINDING PROTEIN, DNA)
ENCODING THE PROTEIN AND)
METHODS OF USE THEREOF")

Patent No.: 5,663,070)
Issued: September 2, 1997)
Atty. File No.: 4588-5)
For: "RECOMBINANT PRODUCTION OF A)
SOLUBLE SPLICE VARIANT OF THE)
FAX (APO-1) ANTIGEN, FAS Δ TM")

Patent No.: 5,652,210)
Issued: July 29, 1997)
Atty. File No.: 4588-5-DIV1)
For: " SOLUBLE SPLICE VARIANT OF THE)
FAX (APO-1) ANTIGEN, FAS Δ TM")

Patent No.: 5,637,486)
Issued: June 10, 1997)
Atty. File No.: 4588-6-1)
For: "METHODS OF IDENTIFYING)
POTENTIALLY THERAPEUTICALLY)
EFFECTIVE AGENTS AND CELL STRAINS)
FOR USE THEREIN")

Patent No.: 5,620,888)
Issued: April 15, 1997)
Atty. File No.: 4588-6-1DIV1)
For: "CELL STRAINS FOR USE IN IDENTIFYING)
POTENTIALLY THERAPEUTICALLY)
EFFECTIVE AGENTS")

Patent No.: 5,681,703)
Issued: October 28, 1997)
Atty. File No.: 4588-6-1DIV2)
For: "METHODS OF IDENTIFYING)
POTENTIALLY THERAPEUTICALLY)
EFFECTIVE AGENTS AND CELL STRAINS)
FOR USE THEREIN")

ASSIGNMENT

WHEREAS, LXR Biotechnology, Inc., a Delaware corporation having a place of business at 1401 Marina Way South, Richmond, California 94804, is the owner of an interest in and to the patents and patent applications listed in Appendix A attached hereto;

WHEREAS, Tanox, Inc., a Delaware corporation having a place of business at 10301 Stella Link, Houston, Texas 77025 is desirous of acquiring said interest of LXR Biotechnology, Inc.

NOW THEREFORE, be it known that for certain good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, LXR Biotechnology, Inc., effective September 25, 2000, does sell, assign and transfer to Tanox, Inc., its successors, legal representatives and assigns, the patents and patent applications listed in Appendix A for the territory of the United States of America and all continuation, divisional, continuation-in-part and reissue applications, all patent applications in foreign countries, all applications pursuant to the Patent Cooperation Treaty and all applications for extension filed or to be filed for the inventions, and all Letters Patent, Invention Registrations, Utility Models, Extensions or Reissues and other patent rights, obtained for the invention in the United States or any other country; LXR Biotechnology, Inc. also assigns any right, title or interest in and to the said inventions which have not already been transferred to Tanox, Inc.; LXR Biotechnology, Inc. warrants that no assignment has been made of the inventions, applications or patents therefor to a party other than Tanox, Inc. and is under no obligation to make any assignment of the inventions, applications, or patents therefor to any other party; and LXR Biotechnology, Inc. further agrees to cooperate with Tanox, Inc. hereunder in the obtaining and sustaining of any and all such Letters Patent and in confirming Tanox, Inc.'s exclusive ownership of the inventions, but at the expense of Tanox, Inc.

The Commissioner of Patents is hereby authorized and requested to issue the Letters Patent solely in accordance with the terms of this Assignment, to Tanox, Inc., its successors, legal representatives and assigns, as the assignee of the entire right, title and interest therein.

IN WITNESS WHEREOF, the parties hereto have executed this Assignment as of the day indicated hereunder.

Date: May 2nd, 2001

By: Paul J. Hastings
Paul J. Hastings, Secretary, Director


STATE OF California)
COUNTY OF San Mateo)

ss.

See Attached Certificate

Before me, a Notary Public in and for said County and State, personally appeared Paul J. Hastings, who acknowledged himself to be the Secretary of LXR Biotechnology, Inc. and that he, as such Secretary, being authorized to do so, executed the foregoing instrument for the purposes and considerations therein expressed, by signing the name of the corporation by himself as Secretary

Given under my hand and seal of office this 3rd day of May, 2001.



Nancy L. Taylor
Notary Public
My commission expires: May 11, 2004

CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT


State of California

County of San Mateo

On May 3, 2001 before me, Nancy L. Taylor, Notary,
Date Name and Title of Office (e.g., "Jane Doe, Notary Public")

personally appeared Paul J. Hastings,
Name(s) of Signer(s)

☒ personally known to me – OR – ☐ proved to me on the basis of satisfactory evidence to be the person ~~or~~
whose name ~~is~~ subscribed to the within instrument
and acknowledged to me that he ~~she~~ he executed the
same in his ~~her~~ his authorized capacity ~~(ies)~~, and that by
his ~~her~~ his signature ~~(s)~~ on the instrument the person ~~or~~
or the entity upon behalf of which the person ~~or~~ acted,
executed the instrument.



WITNESS my hand and official seal.

Nancy L. Taylor
Signature of Notary Public

OPTIONAL

Though the information below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document.

Description of Attached Document

Title or Type of Document: _____

Document Date: _____ Number of Pages: _____

Signer(s) Other Than Named Above: _____

Capacity(ies) Claimed by Signer(s)

Signer's Name: _____

- ☐ Individual
☐ Corporate Officer
Title(s): _____
☐ Partner — ☐ Limited ☐ General
☐ Attorney-in-Fact
☐ Trustee
☐ Guardian or Conservator
☐ Other: _____

Signer Is Representing: _____

RIGHT THUMBPRINT
OF SIGNER
Top of thumb here

Signer's Name: _____

- ☐ Individual
☐ Corporate Officer
Title(s): _____
☐ Partner — ☐ Limited ☐ General
☐ Attorney-in-Fact
☐ Trustee
☐ Guardian or Conservator
☐ Other: _____

Signer Is Representing: _____

RIGHT THUMBPRINT
OF SIGNER
Top of thumb here

Appendix A

File No.	Appl. No. Filing Date	Reg. No. Issue Date	Title
4588-1-1DIV1	08/471,057 6/6/95	6,015,687 1/18/00	Novel Apoptosis-Modulating Proteins, DNA Encoding the Proteins and Methods of Use Thereof
4588-1-1DIV2	08/470,865 6/6/95		Novel Apoptosis-Modulating Proteins, DNA Encoding the Proteins and Methods of Use Thereof
4588-1-1DIV3	08/471,058 6/6/95	5,770,443 6/23/98	Novel Apoptosis-Modulating Proteins, DNA Encoding the Proteins and Methods of Use Thereof
4588-1-1DIV4	09/633,200 8/7/00		Novel Apoptosis-Modulating Proteins, DNA Encoding the Proteins and Methods of Use Thereof
4588-1-2-FWC	08/944,530 10/7/97	5,998,131 12/7/99	Methods of Screening for Therapeutic Agents Using Novel Apoptosis-Modulating Proteins
4588-2	08/937,067 9/24/97		A Family of Genes Encoding Apoptosis-Related Peptides, Peptides Encoded Thereby and Methods of Use Thereof
4588-3-PUS	09/367,750 8/18/99		Bak Promoter Expression System
4588-4-PUS	09/381,488 9/20/99		A Novel Bak binding Protein, DNA Encoding the Protein and Methods of Use Thereof
4588-5	08/152,443 11/15/98	5,663,070 9/2/97	Recombinant Production of a Soluble Splice Variant of the Fas (APO-1) Antigen, Fas Δ TM
4588-5-DIV1	08/444,231 5/18/95	5,652,210 7/29/97	Soluble Splice Variant of the Fas (APO-1) antigen, Fas Δ TM
4588-6-1	08/366,368 12/29/94	5,637,486 6/10/97	Methods of Identifying Potentially Therapeutically Effective Agents and Cell Strains for Use Therein
4588-6-1DIV1	08/484,876 6/6/95	5,620,888 4/15/97	Cell Strains for Use in Identifying Potentially Therapeutically Effective Agents
4588-6-1DIV2	08/741,785 6/6/95	5,681,703 10/28/97	Methods of Identifying Potentially Therapeutically Effective Agents and Cell Strains for Use Therein
4588-7	08/484,339 6/7/95	5,750,360 5/12/98	Method for Quantitatively Measuring Apoptosis